Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing

KRAS is the most frequently mutated oncogene in human cancer, and its activating mutations represent long-sought therapeutic targets. Programmable nucleases, particularly the CRISPR-Cas9 system, provide an attractive tool for genetically targeting KRAS mutations in cancer cells. Here, we show that c...

Descripción completa

Detalles Bibliográficos
Autores principales: Sayed, Shady, Sidorova, Olga A., Hennig, Alexander, Augsburg, Martina, Cortés Vesga, Catherine P., Abohawya, Moustafa, Schmitt, Lukas T., Sürün, Duran, Stange, Daniel E., Mircetic, Jovan, Buchholz, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Genome and Epigenome
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437569/
https://www.ncbi.nlm.nih.gov/pubmed/35802645
http://dx.doi.org/10.1158/0008-5472.CAN-21-2519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437569/
https://www.ncbi.nlm.nih.gov/pubmed/35802645
http://dx.doi.org/10.1158/0008-5472.CAN-21-2519

Ejemplares similares